secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001104659-25-099512
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 8.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros repurchases $181M of stock from ADAR1 & Pontifax at $17.75; plans $194M tender offer
--------------------------------------------------------------------------------

- Agreed to repurchase all shares held by ADAR1 (13.3%) and Pontifax (11.8%) at $17.75/share for ~$181M total.
- Plans to commence tender offer by end of October 2025 for up to $194M of additional shares at $17.75/share.
- Directors Tomer Kariv and Ran Nussbaum resigned from board; Jean-Jacques Bienaimé appointed Nominating Committee Chair.
- Preliminary cash and cash equivalents as of Sept 30, 2025: ~$693.5M.
- Will distribute 25% of any net proceeds from Takeda license agreement received by Dec 31, 2028 to stockholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000110465925099512/0001104659-25-099512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000110465925099512/tm2528773d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-099512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer